
Besides for the above-mentioned compound ebelactone B, an inhibitory effect on cathepsin A has been found for certain dipeptidic phenylalanine derivatives which are described in JP 2005/145839. There is a need for further compounds which inhibit cathepsin A and offer an opportunity for the treatment of the mentioned diseases and further diseases in which cathepsin A plays a role. The present invention satisfies this need by providing the oxygen-substituted 3-heteroaroylamino-propionic acid derivatives of the formula I defined below.

Certain compounds in which a 3-heteroaroylamino-propionic acid moiety can be present, have already been described. For example, in WO 2006/076202 amine derivatives, which modulate the activity of steroid nuclear receptors, are described which carry on the nitrogen atom of the amine function a heteroaroyl group and a further group which is defined very broadly. In US 2004/0072802 broadly-defined beta-amino acid derivatives are described which carry an acyl group on the beta-amino group and are inhibitors of matrix metalloproteases and/or tumor necrosis factor. In WO 2009/080226 and WO 2009/080227, which relate to antagonists of the platelet ADP receptor P2Y12 and inhibit platelet aggregation, pyrazoloylamino-substituted carboxylic acid derivatives are described which, however, additionally carry a carboxylic acid derivative group on the carbon atom carrying the pyrazoloylamino group. Other pyrazoloylamino-substituted compounds, in which the nitrogen atom of the amino group is connected to a ring system and which are inhibitors of the blood clotting enzymes factor Xa and/or factor VIIa, are described in WO 2004/056815.

In one aspect, there is provided a compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is chosen from the series consisting of $C(R^1)$ and N;

D is chosen from the series consisting of $N(R^2)$;

E is chosen from the series consisting of $C(R^3)$ and N;

G is chosen from the series consisting of R^{71}-O-C(O)-, R^{72}-$N(R^{73})$-C(O)-, NC- and tetrazol-5-yl;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, Ar, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^2 is chosen from the series consisting of (C_1-C_7)-alkyl, (C_3-C_7)-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^3 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^{10} is chosen from the series consisting of R^{11}-O-, R^{12}-$N(R^{13})$-C(O)-O- and Het^2-C(O)-O-;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, (C_3-C_7)-cycloalkyl, Ar and Het^3;

R^{12} and R^{13} are independently of each other chosen from the series consisting of hydrogen, R^{15} and Ar;

R^{14} is $(C_1\text{-}C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, $(C_3\text{-}C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, $(C_1\text{-}C_4)$-alkyl-NH-C(O)-, di($(C_1\text{-}C_4)$-alkyl)N-C(O)-, Het^1-C(O)-, $(C_1\text{-}C_4)$-alkyl-C(O)-NH- and $(C_1\text{-}C_4)$-alkyl-$S(O)_m$-;

R^{15} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and $(C_1\text{-}C_6)$-alkyl-O-;

R^{16} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, $(C_1\text{-}C_4)$-alkyl-O- and NC-;

R^{30} is chosen from the series consisting of R^{31}, $(C_3\text{-}C_7)$-cycloalkyl, R^{32}-C_uH_{2u}- and Het^3-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{31} is $(C_1\text{-}C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$- and NC-;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, R^{33}, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di($(C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1\text{-}C_6)$-alkyl-NH-, di($(C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH-, $(C_1\text{-}C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, HO-, (C_1-C_6)-alkyl-
O-, (C_1-C_6)-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, (C_1-C_4)-alkyl-NH-$S(O)_2$-, di$((C_1-C_4)$-alkyl$)N$-$S(O)_2$- and NC-;

R^{40} is chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

or R^{30} and R^{40} together are $(CH_2)_x$ which is optionally substituted by one or more identical or different (C_1-C_4)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{50} is chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, HO- and (C_1-C_6)-alkyl-O-;

R^{60} is chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl;

or R^{50} and R^{60} together are $(CH_2)_y$ which is optionally substituted by one or more identical or different (C_1-C_4)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{71} is chosen from the series consisting of hydrogen and (C_1-C_8)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (C_1-C_6)-alkyl-O- and (C_1-C_6)-alkyl-C(O)-O-;

R^{72} and R^{73} are independently of each other chosen from the series consisting of hydrogen and (C_1-C_2)-alkyl;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which

comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO-, $(C_1$-$C_4)$-alkyl-O-, oxo and
NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO- and $(C_1$-$C_4)$-alkyl-O-;


Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, $(C_1$-$C_4)$-alkyl and oxo;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

In one aspect, there is provided a process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as defined above, comprising reacting a compound of the formula II with a compound of the formula III,



II III I

wherein the groups A, D, E, G, R^{10}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C_1-C_4)-alkyl-O- or halogen.

In one aspect, there is provided a pharmaceutical composition, which comprises at least one compound of the formula I as defined above or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier.

In one aspect, there is provided the use of a compound of the formula I as defined above or a physiologically acceptable salt thereof or a physiologically acceptable solvate

of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics).

In one aspect, there is provided a compound as defined above, which is (S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid or a physiologically acceptable salt thereof.


In one aspect, there is provided a compound as defined above, which is (S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid or a physiologically acceptable salt thereof.

In one aspect, there is provided a compound as defined above, which is (S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid or a physiologically acceptable salt thereof.

In one aspect, there is provided a compound as defined above, which is (S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid or a physiologically acceptable salt thereof.

In one aspect, there is provided a compound as defined above, which is (S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid or a physiologically acceptable salt thereof.


A subject of the present invention is a compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

Claims

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is chosen from the series consisting of $C(R^1)$ and N;

D is chosen from the series consisting of $N(R^2)$, O and S;

E is chosen from the series consisting of $C(R^3)$ and N;

G is chosen from the series consisting of R^{71}-O-C(O)-, R^{72}-N(R^{73})-C(O)-, NC- and tetrazol-5-yl;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, Ar, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^2 is chosen from the series consisting of (C_1-C_7)-alkyl, (C_3-C_7)-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^3 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^{10} is chosen from the series consisting of R^{11}-O-, R^{12}-N(R^{13})-C(O)-O- and Het^2-C(O)-O-;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, $(C_3$-$C_7)$-cycloalkyl, Ar and Het^3;

R^{12} and R^{13} are independently of each other chosen from the series consisting of hydrogen, R^{15} and Ar;

R^{14} is $(C_1$-$C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, $(C_3$-$C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, $(C_1$-$C_4)$-alkyl-NH-C(O)-, di$((C_1$-$C_4)$-alkyl)N-C(O)-, Het^1-C(O)-, $(C_1$-$C_4)$-alkyl-C(O)-NH- and $(C_1$-$C_4)$-alkyl-$S(O)_m$-;

R^{15} is $(C_1$-$C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and $(C_1$-$C_6)$-alkyl-O-;

R^{16} is $(C_1$-$C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, $(C_1$-$C_4)$-alkyl-O- and NC-;

R^{30} is chosen from the series consisting of R^{31}, $(C_3$-$C_7)$-cycloalkyl, R^{32}-C_uH_{2u}- and Het^3-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{31} is $(C_1$-$C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_3$-$C_7)$-cycloalkyl, HO-, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$- and NC-;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, R^{33}, HO-, $(C_1$-$C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1$-$C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1$-$C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1$-$C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1$-$C_6)$-alkyl-NH-

, di((C1-C6)-alkyl)N-, Het[1], (C1-C4)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (C1-C4)-alkyl-S(O)2-NH- and NC-;

R33 is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl, HO-, (C1-C6)-alkyl-O-, (C1-C6)-alkyl-S(O)m-, H2N-S(O)2-, (C1-C4)-alkyl-NH-S(O)2-, di((C1-C4)-alkyl)N-S(O)2- and NC-;

R40 is chosen from the series consisting of hydrogen and (C1-C4)-alkyl;

or R30 and R40 together are (CH2)x which is optionally substituted by one or more identical or different (C1-C4)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R50 is chosen from the series consisting of hydrogen, (C1-C6)-alkyl, HO- and (C1-C6)-alkyl-O-;

R60 is chosen from the series consisting of hydrogen and (C1-C6)-alkyl;

or R50 and R60 together are (CH2)y which is optionally substituted by one or more identical or different (C1-C4)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R71 is chosen from the series consisting of hydrogen and (C1-C8)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (C1-C6)-alkyl-O- and (C1-C6)-alkyl-C(O)-O-;

R^{72} is chosen from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_6)$-cycloalkyl, $-CH_2\text{-}(CH_2)_b\text{-}(C_3\text{-}C_6)$-cycloalkyl, Het^4 and $\text{-}(CH_2)_b\text{-}Het^4$, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, $(C_1\text{-}C_6)$-alkyl-O- and $(C_1\text{-}C_6)$-alkyl-C(O)-O-, NC-, $N((C_1\text{-}C_4)\text{-alkyl})_2$ and b is 0, 1 or 2;

R^{73} is chosen from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl;

or

R^{72} and R^{73} together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_4)$-alkyl, HO- and $(C_1\text{-}C_4)$-alkyl-O-;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl-O-, $\text{-O-}CH_2\text{-O-}$, $\text{-O-}CF_2\text{-O-}$, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, $H_2N\text{-}S(O)_2$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_4)$-alkyl, HO-, $(C_1\text{-}C_4)$-alkyl-O-, oxo and NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring

heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO- and (C_1-C_4)-alkyl-O-;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (C_1-C_4)-alkyl and oxo;

Het^4, independently of each other group Het^4, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO-, (C_1-C_4)-alkyl-O-, oxo and NC-;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein E is N.

3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 and 2, wherein D is $N(R^2)$.

4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 3, wherein

A is chosen from the series consisting of $C(R^1)$ and N;

D is $N(R^2)$;

E is N;

R^1 is chosen from the series consisting of hydrogen, halogen and (C_1-C_4)-alkyl;

R^2 is $Ar\text{-}C_sH_{2s}$-, wherein s is an integer chosen from the series consisting of 0, 1 and 2.

5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 4, wherein R^{10} is R^{11}-O-.

6. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 5, wherein R^{30} is $R^{32}\text{-}C_uH_{2u}$- wherein u is an integer chosen from the series consisting of 0 and 1.

7. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 6, wherein

G is chosen from the series consisting of R^{71}-O-C(O)- and R^{72}-$N(R^{73})$-C(O)-;

R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;
R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, R^{33}, (C_1-C_6)-alkyl-O-, R^{33}-O-, R^{33}-(C_1-C_4)-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, (C_1-C_6)-alkyl-S(O)$_m$-, (C_1-C_6)-alkyl-NH-, di((C_1-C_6)-alkyl)N-, Het^1 and NC-;
R^{33} is chosen from the series consisting of phenyl and pyridinyl which all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, (C_1-C_4)-alkyl-O-, (C_1-C_4)-alkyl-S(O)$_m$- and NC-;
R^{40} is hydrogen;
R^{50} is hydrogen;
R^{60} is hydrogen.

8. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 7, wherein

A is chosen from the series consisting of C(R^1) and N;

D is N(R^2);

E is chosen from the series consisting of C(R^3) and N;

G is chosen from the series consisting of R^{71}-O-C(O)- and R^{72}-N(R^{73})-C(O)-;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, HO- and (C_1-C_6)-alkyl-O-;

R^2 is chosen from the series consisting of $(C_1$-$C_7)$-alkyl, $(C_3$-$C_7)$-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^3 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl and $(C_1$-$C_6)$-alkyl-O-;

R^{10} is chosen from the series consisting of R^{11}-O-, R^{12}-N(R^{13})-C(O)-O- and Het^2-C(O)-O-;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, $(C_3$-$C_7)$-cycloalkyl and Het^3;

R^{12} and R^{13} are independently of each other chosen from the series consisting of hydrogen, R^{15} and Ar;

R^{14} is $(C_1$-$C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, $(C_3$-$C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, $(C_1$-$C_4)$-alkyl-NH-C(O)-, di$((C_1$-$C_4)$-alkyl)N-C(O)- and Het^1-C(O)-;

R^{15} is $(C_1$-$C_6)$-alkyl;

R^{16} is $(C_1$-$C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO- and $(C_1$-$C_4)$-alkyl-O-;

R^{30} is chosen from the series consisting of $(C_3$-$C_7)$-cycloalkyl, R^{32}-C_uH_{2u}- and Het^3-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, R^{33}, HO-, $(C_1$-$C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1$-

C_4)-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, (C_1-C_6)-alkyl-S(O)$_m$-, di((C_1-C_4)-alkyl)N-S(O)$_2$-, H_2N-, di((C_1-C_6)-alkyl)N-, Het^1, (C_1-C_4)-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-S(O)$_m$-, H_2N-S(O)$_2$-, di((C_1-C_4)-alkyl)N-S(O)$_2$- and NC-;

R^{40} is hydrogen;

R^{50} is chosen from the series consisting of hydrogen and HO-;

R^{60} is hydrogen;

R^{71} is chosen from the series consisting of hydrogen and (C_1-C_8)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (C_1-C_6)-alkyl-O- and (C_1-C_6)-alkyl-C(O)-O-;

R^{72} and R^{73} are independently of each other chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, (C_1-C_6)-alkyl-S(O)$_m$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO-, $(C_1$-$C_4)$-alkyl-O-, oxo and NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO- and $(C_1$-$C_4)$-alkyl-O-;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, $(C_1$-$C_4)$-alkyl and oxo;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents;

9. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 8, wherein

A is $C(R^1)$;

D is $N(R^2)$;

E is N;

G is chosen from the series consisting of R^{71}-O-C(O)- and R^{72}-N(R^{73})-C(O)-;

R^1 is chosen from the series consisting of hydrogen, halogen and (C_1-C_4)-alkyl;

R^2 is Ar-C_sH_{2s}-, wherein s is 0;

R^{10} is R^{11}-O-;

R^{11} is chosen from the series consisting of hydrogen and R^{14};

R^{14} is (C_1-C_{10})-alkyl which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of HO-, R^{16}-O-, oxo, (C_3-C_7)-cycloalkyl, Ar, Het^1, di((C_1-C_4)-alkyl)N- and Het^1-C(O)-;

R^{16} is (C_1-C_6)-alkyl which is optionally substituted by one or two identical or different substituents chosen from the series consisting of HO- and (C_1-C_4)-alkyl-O-;

R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;

R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, R^{33}, $(C_1$-$C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1$-$C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-S(O)$_m$-, di$((C_1$-$C_6)$-alkyl)N-, Het^1 and NC-;

R^{33} is chosen from the series consisting of phenyl and pyridinyl which all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_1$-$C_4)$-alkyl-O-, $(C_1$-$C_4)$-alkyl-S(O)$_m$- and NC-;

R^{40} is hydrogen;

R^{50} is hydrogen;

R^{60} is hydrogen;

R^{71} is chosen from the series consisting of hydrogen and $(C_1$-$C_8)$-alkyl which is optionally substituted by one substituent chosen from the series consisting $(C_1$-$C_6)$-alkyl-O- and $(C_1$-$C_6)$-alkyl-C(O)-O-;

R^{72} and R^{73} are independently of each other chosen from the series consisting of hydrogen and $(C_1$-$C_2)$-alkyl;

Ar is chosen from the series consisting of phenyl and an aromatic 6-membered heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle are all optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-S(O)$_m$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 6-membered monocyclic heterocycle which comprises a ring nitrogen

atom via which Het^1 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of fluorine, (C_1-C_4)-alkyl, HO- and oxo;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s} and C_uH_{2u} groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

10. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 9, chosen from

3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-phenyl)-propionic acid,

3-(3-tert-Butoxy-phenyl)-3-{[1-(2,5-dimethyl-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

3-(3-Fluoro-2-methyl-phenyl)-3-{[1-(4-fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-(2-Chloro-5-fluoro-phenyl)-3-{[1-(4-fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-[(5-Methoxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid,


3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy-5-trifluoromethyl-phenyl)-propionic acid,

3-(2-Fluoro-4-methyl-phenyl)-3-[(5-hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-propionic acid,
3-{[1-(2-Chloro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-3-(2'-fluoro-biphenyl-4-yl)-propionic acid,
3-[(5-Methoxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(4-pyridin-2-yl-phenyl)-propionic acid,
3-{[1-(2-Fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-3-(4-methanesulfonyl-phenyl)-propionic acid,
(S)-3-{[5-Hydroxy-1-(2-methanesulfonyl-phenyl)-1H)-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(4-methoxy-2-methyl-phenyl)-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid,
3-(2,3-Dimethyl-phenyl)-3-{[1-(2-fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
3-{[5-Cyclopropylmethoxy-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-(3-fluoro-2-methyl-phenyl)-propionic acid,
(S)-3-{[5-Cyclopropylmethoxy-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-(2-hydroxy-2-methyl-propoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[5-(2-Cyclopropyl-2-hydroxy-propoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2-ethyl-2-hydroxy-butoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid,
(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-1-phenyl-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid,
(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1-phenyl-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid,
(S)-3-{[1-(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid, and
(S)-3-{[1-(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid.

11. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any

one or more of claims 1 to 10, comprising reacting a compound of the formula II with a compound of the formula III,



II III I

wherein the groups A, D, E, G, R^{10}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C_1-C_4)-alkyl-O- or halogen.

12. A compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for use as a pharmaceutical.


13. A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier.

14. Use of a compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain,

ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics)

Claims

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is chosen from the series consisting of $C(R^1)$ and N;

D is chosen from the series consisting of $N(R^2)$;

E is chosen from the series consisting of $C(R^3)$ and N;

G is chosen from the series consisting of R^{71}-O-C(O)-, R^{72}-$N(R^{73})$-C(O)-, NC- and tetrazol-5-yl;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, Ar, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^2 is chosen from the series consisting of (C_1-C_7)-alkyl, (C_3-C_7)-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^3 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$- and NC-;

R^{10} is chosen from the series consisting of R^{11}-O-, R^{12}-$N(R^{13})$-C(O)-O- and Het^2-C(O)-O-;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, (C_3-C_7)-cycloalkyl, Ar and Het^3;

R^{12} and R^{13} are independently of each other chosen from the series consisting of hydrogen, R^{15} and Ar;

R^{14} is $(C_1\text{-}C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, $(C_3\text{-}C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, $(C_1\text{-}C_4)$-alkyl-NH-C(O)-, di($(C_1\text{-}C_4)$-alkyl)N-C(O)-, Het^1-C(O)-, $(C_1\text{-}C_4)$-alkyl-C(O)-NH- and $(C_1\text{-}C_4)$-alkyl-$S(O)_m$-;

R^{15} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and $(C_1\text{-}C_6)$-alkyl-O-;

R^{16} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, $(C_1\text{-}C_4)$-alkyl-O- and NC-;

R^{30} is chosen from the series consisting of R^{31}, $(C_3\text{-}C_7)$-cycloalkyl, R^{32}-C_uH_{2u}- and Het^3-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{31} is $(C_1\text{-}C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$- and NC-;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, R^{33}, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di($(C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1\text{-}C_6)$-alkyl-NH-, di($(C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH-, $(C_1\text{-}C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-
O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, $H_2N\text{-}S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di$((C_1\text{-}C_4)$-alkyl)N-$S(O)_2$- and NC-;

R^{40} is chosen from the series consisting of hydrogen and $(C_1\text{-}C_4)$-alkyl;

or R^{30} and R^{40} together are $(CH_2)_x$ which is optionally substituted by one or more identical or different $(C_1\text{-}C_4)$-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{50} is chosen from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl, HO- and $(C_1\text{-}C_6)$-alkyl-O-;

R^{60} is chosen from the series consisting of hydrogen and $(C_1\text{-}C_6)$-alkyl;

or R^{50} and R^{60} together are $(CH_2)_y$ which is optionally substituted by one or more identical or different $(C_1\text{-}C_4)$-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{71} is chosen from the series consisting of hydrogen and $(C_1\text{-}C_8)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting $(C_1\text{-}C_6)$-alkyl-O- and $(C_1\text{-}C_6)$-alkyl-C(O)-O-;

R^{72} and R^{73} are independently of each other chosen from the series consisting of hydrogen and $(C_1\text{-}C_2)$-alkyl;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which

comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, $-O-CH_2-O-$, $-O-CF_2-O-$, (C_1-C_6)-alkyl-$S(O)_m$-, $H_2N-S(O)_2$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO-, (C_1-C_4)-alkyl-O-, oxo and
NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO- and (C_1-C_4)-alkyl-O-;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (C_1-C_4)-alkyl and oxo;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein E is N.

3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 or 2, wherein
A is chosen from the series consisting of $C(R^1)$ and N;
D is $N(R^2)$;
E is N;
R^1 is chosen from the series consisting of hydrogen, halogen and (C_1-C_4)-alkyl;
R^2 is Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1 and 2.

4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 3, wherein R^{10} is R^{11}-O-.

5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 4, wherein R^{30} is R^{32}-C_uH_{2u}- wherein u is an integer chosen from the series consisting of 0 and 1.

6. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 5, wherein

G is chosen from the series consisting of R^{71}-O-C(O)- and R^{72}-N(R^{73})-C(O)-;

R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;

R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, R^{33}, (C_1-C_6)-alkyl-O-, R^{33}-O-, R^{33}-(C_1-C_4)-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, (C_1-C_6)-alkyl-S(O)$_m$-, (C_1-C_6)-alkyl-NH-, di((C_1-C_6)-alkyl)N-, Het^1 and NC-;

R^{33} is chosen from the series consisting of phenyl and pyridinyl which all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, (C_1-C_4)-alkyl-O-, (C_1-C_4)-alkyl-S(O)$_m$- and NC-;

R^{40} is hydrogen;

R^{50} is hydrogen;

R^{60} is hydrogen.

7. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein

A is chosen from the series consisting of C(R^1) and N;

D is N(R^2);

E is chosen from the series consisting of C(R^3) and N;

G is chosen from the series consisting of R^{71}-O-C(O)- and R^{72}-N(R^{73})-C(O)-;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, HO- and (C_1-C_6)-alkyl-O-;

R^2 is chosen from the series consisting of (C_1-C_7)-alkyl, (C_3-C_7)-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^3 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl and (C_1-C_6)-alkyl-O-;

R^{10} is chosen from the series consisting of R^{11}-O-, R^{12}-N(R^{13})-C(O)-O- and Het^2-C(O)-O-;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, (C_3-C_7)-cycloalkyl and Het^3;

R^{12} and R^{13} are independently of each other chosen from the series consisting of hydrogen, R^{15} and Ar;

R^{14} is (C_1-C_{10})-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, (C_3-C_7)-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, (C_1-C_4)-alkyl-NH-C(O)-, di((C_1-C_4)-alkyl)N-C(O)- and Het^1-C(O)-;

R^{15} is (C_1-C_6)-alkyl;

R^{16} is (C_1-C_6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO- and (C_1-C_4)-alkyl-O-;

R^{30} is chosen from the series consisting of (C_3-C_7)-cycloalkyl, R^{32}-C_uH_{2u}- and Het^3-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, R^{33}, HO-, $(C_1$-$C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1$-$C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-S$(O)_m$-, di$((C_1$-$C_4)$-alkyl)N-S$(O)_2$-, H_2N-, di$((C_1$-$C_6)$-alkyl)N-, Het[1], $(C_1$-$C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, HO-, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-S$(O)_m$-, H_2N-S$(O)_2$-, di$((C_1$-$C_4)$-alkyl)N-S$(O)_2$- and NC-;

R^{40} is hydrogen;

R^{50} is chosen from the series consisting of hydrogen and HO-;

R^{60} is hydrogen;

R^{71} is chosen from the series consisting of hydrogen and $(C_1$-$C_8)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting $(C_1$-$C_6)$-alkyl-O- and $(C_1$-$C_6)$-alkyl-C(O)-O-;

R^{72} and R^{73} are independently of each other chosen from the series consisting of hydrogen and $(C_1$-$C_2)$-alkyl;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1$-$C_6)$-alkyl-S$(O)_m$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO-, $(C_1$-$C_4)$-alkyl-O-, oxo and
NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO- and $(C_1$-$C_4)$-alkyl-O-;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, $(C_1$-$C_4)$-alkyl and oxo;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents;

8. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein

A is $C(R^1)$;

D is $N(R^2)$;

E is N;

R^1 is chosen from the series consisting of hydrogen, halogen and $(C_1$-$C_4)$-alkyl;

R^2 is Ar-C_sH_{2s}-, wherein s is 0;

R^{10} is R^{11}-O-;

R^{11} is chosen from the series consisting of hydrogen and R^{14};

R^{14} is $(C_1$-$C_{10})$-alkyl which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of HO-, R^{16}-O-, oxo, $(C_3$-$C_7)$-cycloalkyl, Ar, Het^1, di$((C_1$-$C_4)$-alkyl)N- and Het^1-C(O)-;

R^{16} is $(C_1$-$C_6)$-alkyl which is optionally substituted by one or two identical or different substituents chosen from the series consisting of HO- and $(C_1$-$C_4)$-alkyl-O-;

R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;

R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, R^{33}, $(C_1$-$C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1$-

C_4)-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, (C_1-C_6)-alkyl-S(O)$_m$-, di((C_1-C_6)-alkyl)N-, Het^1 and NC-;

R^{33} is chosen from the series consisting of phenyl and pyridinyl which all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, (C_1-C_4)-alkyl-O-, (C_1-C_4)-alkyl-S(O)$_m$- and NC-;

R^{40} is hydrogen;

R^{50} is hydrogen;

R^{60} is hydrogen;

R^{71} is chosen from the series consisting of hydrogen and (C_1-C_8)-alkyl which is optionally substituted by one substituent chosen from the series consisting (C_1-C_6)-alkyl-O- and (C_1-C_6)-alkyl-C(O)-O-;

R^{72} and R^{73} are independently of each other chosen from the series consisting of hydrogen and (C_1-C_2)-alkyl;

Ar is chosen from the series consisting of phenyl and an aromatic 6-membered heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle are all optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-S(O)$_m$- and NC-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 6-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of fluorine, (C_1-C_4)-alkyl, HO- and oxo;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s} and C_uH_{2u} groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

9. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 8, chosen from
3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-phenyl)-propionic acid,
3-(3-tert-Butoxy-phenyl)-3-{[1-(2,5-dimethyl-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
3-(3-Fluoro-2-methyl-phenyl)-3-{[1-(4-fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
3-(2-Chloro-5-fluoro-phenyl)-3-{[1-(4-fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-[(5-Methoxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid,
3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy-5-trifluoromethyl-phenyl)-propionic acid,
3-(2-Fluoro-4-methyl-phenyl)-3-[(5-hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-propionic acid,
3-{[1-(2-Chloro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-3-(2'-fluoro-biphenyl-4-yl)-propionic acid,
3-[(5-Methoxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(4-pyridin-2-yl-phenyl)-propionic acid,

3-{[1-(2-Fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-3-(4-methanesulfonyl-phenyl)-propionic acid,

(S)-3-{[5-Hydroxy-1-(2-methanesulfonyl-phenyl)-1H)-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(4-methoxy-2-methyl-phenyl)-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid,

3-(2,3-Dimethyl-phenyl)-3-{[1-(2-fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-{[5-Cyclopropylmethoxy-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-(3-fluoro-2-methyl-phenyl)-propionic acid,

(S)-3-{[5-Cyclopropylmethoxy-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-(2-hydroxy-2-methyl-propoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[5-(2-Cyclopropyl-2-hydroxy-propoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,


(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2-ethyl-2-hydroxy-butoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid,
(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-1-phenyl-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid,
(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1-phenyl-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid,
(S)-3-{[1-(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid, and
(S)-3-{[1-(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-phenyl-propionic acid.

10. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any one or more of claims 1 to 9, comprising reacting a compound of the formula II with a compound of the formula III,



II III I

wherein the groups A, D, E, G, R^{10}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally

functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C_1-C_4)-alkyl-O- or halogen.

11. A compound of the formula I as claimed in any one or more of claims 1 to 9 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for use as a pharmaceutical.

12. A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 9 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier.

13. Use of a compound of the formula I as claimed in any one or more of claims 1 to 9 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics).

14. A compound
according to claim 1, which is
(S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid or a physiologically acceptable salt thereof.

15. A compound
according to claim 1, which is

(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid or a physiologically acceptable salt thereof.

16. A compound
according to claim 1, which is
(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid or a physiologically acceptable salt thereof.

17. A compound
according to claim 1, which is
(S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid or a physiologically acceptable salt thereof.

18. A compound
according to claim 1, which is
(S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino}-propionic acid or a physiologically acceptable salt thereof.